Mpox Videos, Digital Banners, Graphics and More!
Free to use, downloadable mpox content. Share on social media, embed on websites, link to in e-communications, and more.
Free to use, downloadable mpox content. Share on social media, embed on websites, link to in e-communications, and more.
This webpage discusses how viral hepatitis has a disproportionate impact in Hispanic/Latinx communities. As of 2018, the year data was most recently available, Hispanic/Latinx individuals were 1.4x more likely to die from Hepatitis C than non-Hispanic white people. Hispanic/Latinx communities face multiple barriers to viral hepatitis prevention, treatment care, and research, such as language, access to available quality care and insurance, patient education, history of incarceration or injection drug use, and high-risk behavior.
Contact organization for eligibility
Contact organization for eligibility
Contact organization for eligibility
Contact organization for eligibility
This webinar recording discusses how to reduce disparities in hepatitis, research and community partnerships have been essential in reaching at-risk and underserved populations by addressing the adverse social determinants that are responsible for these disparities. For example, successful collaborations often simplify and facilitate access and linkage to care. In many cases, communities are considered as program recipients or research subjects instead of critical partners who should be significant contributors to the design and implementation of an initiative.
This webinar, translated in French, discusses how every year, 1.3 million people lose their lives to hepatitis – because they weren’t tested, or didn’t have access to treatment, or were never vaccinated. And new data from the World Health Organization shows the number of deaths is rising.
This video presentation by the San Francisco Department of Public Health (SFDPH) on implementation of Doxy-PEP in a single clinic which offered Doxy-PEP to all clients using HIV PrEP and saw bacterial STIs decrease among those who used Doxy-PEP by nearly 60% in less than a year, with the highest declines for syphilis (78%) and chlamydia (67%).